PAUL CHECCHIA to Palivizumab
This is a "connection" page, showing publications PAUL CHECCHIA has written about Palivizumab.
Connection Strength
0.400
-
CHD and respiratory syncytial virus: global expert exchange recommendations. Cardiol Young. 2017 Oct; 27(8):1504-1521.
Score: 0.143
-
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011 Sep; 12(5):580-8.
Score: 0.096
-
Rate of palivizumab administration in accordance with current recommendations among hospitalized children. J Pediatr Health Care. 2004 Sep-Oct; 18(5):224-7.
Score: 0.059
-
SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. Am J Perinatol. 2020 03; 37(4):421-429.
Score: 0.041
-
SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. Am J Perinatol. 2017 01; 34(1):51-61.
Score: 0.033
-
Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Hum Vaccin Immunother. 2014; 10(3):607-14.
Score: 0.028